If you were one of the roughly 41 scientists let go from Foghorn Therapeutics on Oct 1, 2026, your resume problem is not the one the layoff advice columns are solving. Your program failed in Phase 1, Eli Lilly walked away from a deal originally valued at up to $1.6 billion, and the Fierce Biotech Layoff Tracker has your employer's name on it. The question is not how to hide any of that. It is how to turn a hyper-specialized, scientifically failed program into the strongest line on your CV.
What actually happened at Foghorn on Oct 1
Foghorn Therapeutics cut about 40% of its staff on Oct 1, 2026 after it and Eli Lilly jointly decided on Sept 25 not to advance FHD-909 past Phase 1 dose escalation, ending a 2021 oncology collaboration originally worth up to $1.6 billion. The board approved the restructuring on Sept 30 and the company announced it the next morning.
The numbers that recruiters will Google before they open your resume:
- Headcount: 106 at the end of 2025, falling to about 65 after the cut, which puts the layoff at roughly 41 roles (headlines rounding to "~43" are directionally fine).
- Stock: shares fell about 49% to $1.84 on the Lilly termination news.
- Restructuring charges: about $2.3 million.
- Cash: $167.6 million on hand as of June 30, 2026, with runway extended into the second half of 2029.
- Clinical pipeline: zero clinical-stage programs left. Earliest planned IND is 2027.
- Location: Watertown, MA. Not Cambridge, despite what several outlets wrote.
Shares closed near $1.84 on the Oct 1 termination, which is the price a recruiter will see when they look you up.
The second thing to internalize: this is Foghorn's second clinical failure in two years. FHD-286 was discontinued in late 2024 after it failed in a leukemia trial. A whole cohort of Foghorn alumni already walked this exact path, and most of them landed. That matters for how you work the network, which I will come back to.
Why the "mechanism failed, not the team" framing is defensible
The cleanest way to own a failed Phase 1 on a resume is to borrow the language the CEO used publicly: safety profile intact, exposures achieved, biology did not translate. That is a mechanism failure, not an execution failure, and the scientific community already treats SMARCA2/4 synthetic lethality as a legitimate hypothesis that got rigorously tested.
Here is the exact Adrian Gottschalk framing, which you can quote or paraphrase in a cover letter without inventing anything: "the biology of the SMARCA2/4 synthetic lethality relationship has not translated into the level of efficacy required to further advance the program."
That sentence does three things at once:
- It confirms the drug was selective and safe, so the chemistry and translational work held up.
- It locates the failure at the biological hypothesis layer, where no individual team member owns it.
- It uses the vocabulary a hiring scientific director at Nurix, Monte Rosa, or Kymera already uses in their own internal reviews.
Compare that to Replimune, which lost an additional 161 people (about 60% of staff) after an FDA rejection, or Bicycle Therapeutics, which shed 86 of 288 employees after the FDA declared the zelenectide pathway no longer viable. Those are regulatory failures. The resume framing there is different: you lean on the data package you built. For Foghorn alumni the lean is on the mechanism and the quality of the clinical readout itself. Do not conflate the two.
A Phase 1 that cleanly kills a hypothesis is a better line on a resume than a Phase 2 that drags on another two years saying nothing.
The TPD talent pool is small enough that 41 people move the market
In Refolk's index of professional profiles, only about 137 US people credibly describe meaningful targeted protein degradation or PROTAC experience, and only 10 of those sit in the Scientist, Senior Scientist, Principal, or Associate Director band inside oncology biotech. The Oct 1 Foghorn cohort is not a rounding error in this talent market. It is a visible fraction of it.
| Segment | US profiles | Source |
|---|---|---|
| TPD / PROTAC skills, any seniority | 137 | Refolk's index |
| Same, filtered to Scientist through Assoc Director in oncology biotech | 10 | Refolk's index |
| Share of TPD pool in the Foghorn seniority band | ~7.3% | Derived |
| Top absorbing employer (TPD talent) | Nurix Therapeutics (3 profiles) | Refolk's index |
| Share of top TPD employers in Greater Boston / Cambridge | ~20% | Derived |
| Foghorn headcount, pre vs post | 106 → ~65 (-39%) | Fierce / Reuters |
In Refolk's index, that is the entire national pool your cohort is competing inside. Scarcity is leverage, not a liability.
The practical read: do not write your resume as if you are one of ten thousand bench scientists. Write it as if you are one of roughly 137 people in the country who has actually run a chromatin-remodeler degrader program through IND and into first-in-human. Name the modality in the summary line. Name SMARCA2, SMARCA4, EP300, CBP, BAF complex, synthetic lethality, induced proximity. These are search terms the ten recruiters who actually hire in this niche have saved queries for.
This is the exact spot where a generic resume rewrite hurts you. The tailoring that matters is swapping the vocabulary stack per posting (PROTAC vs molecular glue vs induced proximity vs chromatin biology) without losing the specificity. Paste a Nurix or Monte Rosa posting into Refolk and the resume it hands back keeps the SMARCA2 and FHD-909 lines where they belong and reorders everything else around the posting's own language.
Where to send the resume, in order
Target the surviving Foghorn modalities at competitors first, then the broader TPD employer map, then adjacent chromatin and oncology shops. Specifically:
- Nurix Therapeutics. Leads the TPD employer list in Refolk's index with 3 profiles. First call.
- Monte Rosa Therapeutics. Molecular glue degraders, Boston-connected. Natural fit for anyone with BAF-complex or chromatin experience.
- Arvinas, C4 Therapeutics, Kymera Therapeutics. The core PROTAC and degrader cohort. All have overlapping biology interests.
- Lyterian Therapeutics. Appears in the TPD employer list and runs degrader-adjacent chemistry.
- Eli Lilly's own degrader group. Yes, really. Two Lilly profiles showed up in Refolk's TPD slice, which suggests the group that just walked from FHD-909 may quietly backfill from the Foghorn cohort. The partnership ending is not personal, and the hiring managers inside Lilly's degrader team know the FHD-909 data better than almost anyone.
- Foghorn's surviving pipeline teams. EP300 degrader, CBP degrader, the oral immunology and inflammation program, and the induced proximity platform are the 65 jobs that stayed. If you were on an adjacent team and your work maps, ask for an internal transfer before you walk.
Watertown is not Cambridge, and that matters for your search radius
List "Greater Boston" on your resume, not "Cambridge." Watertown commutes cleanly to the Kendall cluster and out to the 128 belt (Framingham, Waltham, Lexington), and recruiter searches that key off "Cambridge" will miss postings in Waltham that you can be at in 20 minutes. This is a trivial edit that changes which saved searches your profile hits.
The FHD-286 cohort is your warm-intro network
Before you send a single cold application, mine the late-2024 FHD-286 layoff cohort on LinkedIn, because they already placed and they have already de-risked the "Foghorn alum" label at specific destinations. The hiring managers who took the first Foghorn wave know what the training was like, know the quality of the chromatin work, and have an opinion about it already. You want to walk into that pre-formed opinion warm, not cold.
Specifically:
- Pull the list of FHD-286 era departures (late 2024 through early 2025) from LinkedIn by filtering "past company: Foghorn Therapeutics" and sorting by role change date.
- Note which employers absorbed more than one. Those are the pattern-matched destinations.
- Message the alum, not the recruiter: "I was on the FHD-909 team. Saw you landed at [X]. Would value 15 minutes on how they received the Foghorn background." Keep it that short.
- Only then apply through the posting.
The ask is small and the hit rate on messages from recent alumni to older alumni of the same employer is unusually high in biotech, where the social graph is tight and failed programs are a shared experience, not a scarlet letter.
What the resume itself needs to say
Lead with the program and the mechanism, not the layoff. Three concrete rewrites:
- Summary line. Replace "Senior Scientist with X years in oncology" with "Senior Scientist, chromatin biology and targeted protein degradation. Led in vivo pharmacology for FHD-909 (SMARCA2 selective degrader) through IND-enabling studies and Phase 1 dose escalation."
- Program bullet. Do not write "program discontinued." Write "FHD-909 Phase 1 dose escalation completed; selective SMARCA2 degradation and target engagement confirmed; program closed when SMARCA2/4 synthetic lethality did not translate to efficacy threshold."
- Partnership bullet. Do not hide the Lilly line. Write "Co-development with Eli Lilly under 2021 oncology collaboration; delivered joint translational package through Phase 1 readout."
Every one of those sentences is factually defensible, uses the CEO's own public framing, and gives a reviewing scientist at Nurix or Kymera a reason to open the full CV. If writing those three lines from scratch for every posting sounds like the kind of work you would rather not do while you are also calling five alumni a day, that is the exact job Refolk takes off the pile: paste the Nurix posting, get your own resume back with the SMARCA2 line reframed for Nurix's own vocabulary, plus a cover letter drafted in the same voice.
A last tactical note: the Fierce Biotech Layoff Tracker 2026 lists Foghorn. Being on that list is not the stigma it feels like from the inside. Recruiters in this niche read the tracker as a sourcing document, not a blacklist. In Q1 2026 alone, 14 Massachusetts life sciences employers announced layoffs affecting at least 745 people. You are one of a visible, specific, well-credentialed cohort inside that number, and the people hiring in TPD know exactly what you were working on.
FAQ
Should I mention FHD-909 by name on my resume?
Yes. The program is public, the Phase 1 result is public, and the hiring managers you want to reach already know the data. Naming the program lets a reviewing scientist place your work immediately on the SMARCA2/4 synthetic lethality map. Hiding it reads as either unfamiliarity with your own program or an attempt to launder the layoff, both of which hurt more than the failure itself.
How do I frame the Lilly partnership ending without sounding defensive?
Use the mechanism framing, not the business framing. The partnership ended because the biology did not translate to the efficacy bar, not because the chemistry or clinical operations failed. Quote or paraphrase Gottschalk's public line about SMARCA2/4 synthetic lethality not translating, and let the reviewing scientist draw their own conclusion. Do not editorialize about Lilly's decision.
Is Boston still a viable job market for a chromatin biology scientist in late 2026?
Yes, but it is tight. In Q1 2026, 14 Massachusetts life sciences companies announced layoffs affecting at least 745 employees, which means the local pool is saturated with recent alumni. The TPD and chromatin niche is narrow enough that the national pool is only around 137 US profiles, so you are competing with a small, identifiable cohort for a small, identifiable set of seats at Nurix, Monte Rosa, Kymera, Arvinas, C4, and Lyterian. Expand the radius out to the 128 belt and list "Greater Boston" not "Cambridge" to catch more postings.
Does being on the Fierce Biotech Layoff Tracker hurt my chances?
No. Recruiters in biotech use the tracker as a sourcing list, not a disqualifier. Failed Phase 1 readouts are a known part of the industry, and a cleanly closed program with public data behind the decision is easier to explain than an ambiguous departure. What hurts is pretending the failure did not happen or burying the program name. Owning the mechanism and naming the compound is the shorter path.